According to the reports, a primary two-dose schedule and a heterologous booster dosage for iNCOVACC have been approved.
Phase-III trials to evaluate safety and immunogenicity of the intranasal COVID-19 vaccine were conducted in about 3100 participants in 14 trial sites across India.
Bharat Biotech had sought permission from DCGI to conduct the phase-3 study in December 2021. The trials would be conducted at nine different sites, including AIIMS Delhi.
Bharat Biotech's intranasal vaccine for Covid-19 has been given a nod by official authorities and is currently undergoing trials. But will it be a game-changer in the fight against the deadly virus?
Bharat Biotech is working on a nasal vaccine, which is expected to be launched by the end of the year. Read on to know the benefits of intranasal Covid-19 vaccines.
Researchers have developed an intranasal COVID-19 vaccine that appears to fully block transmission of the virus. Read on to know more.
According to the reports, a primary two-dose schedule and a heterologous booster dosage for iNCOVACC have been approved.
Phase-III trials to evaluate safety and immunogenicity of the intranasal COVID-19 vaccine were conducted in about 3100 participants in 14 trial sites across India.
Bharat Biotech had sought permission from DCGI to conduct the phase-3 study in December 2021. The trials would be conducted at nine different sites, including AIIMS Delhi.
Bharat Biotech's intranasal vaccine for Covid-19 has been given a nod by official authorities and is currently undergoing trials. But will it be a game-changer in the fight against the deadly virus?
Bharat Biotech is working on a nasal vaccine, which is expected to be launched by the end of the year. Read on to know the benefits of intranasal Covid-19 vaccines.
Researchers have developed an intranasal COVID-19 vaccine that appears to fully block transmission of the virus. Read on to know more.
